HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the JMP Securities Life Sciences Conference being held in New York City, June 15 - 16, 2022.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media Investors
Michael Szumera Matt Beck
Executive Director - Communications Executive Director - Investor Relations
michael.szumera@hookipapharma.com matthew.beck@hookipapharma.com
+1 917 561 8905 +1 917 209 6886
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more HOOKIPA Pharma Charts.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more HOOKIPA Pharma Charts.